Peptides Similar to Semax

Peptides Related to Semax#

Semax (ACTH(4-7)-PGP) is a synthetic nootropic and neuroprotective peptide with regulatory approval in Russia and decades of clinical use. Its position as one of the few peptides with actual pharmaceutical status (albeit limited to Russian markets) makes comparisons with other cognitive and neuroprotective peptides particularly informative.

The most relevant comparisons involve other Russian-developed neuropeptides (Selank, Pinealon), established neuroprotective agents (Cerebrolysin), and newer cognitive peptides under preclinical investigation (Dihexa).

Semax vs Selank#

The comparison between Semax and Selank is the most natural and frequently discussed, as both peptides share a common design platform (the PGP C-terminal stabilization strategy) and were developed at the same institution (Institute of Molecular Genetics, Russian Academy of Sciences).

Shared Design Platform#

Both peptides follow the same structural template: a bioactive tetrapeptide core extended with a C-terminal Pro-Gly-Pro (PGP) tripeptide for metabolic stability. This shared design philosophy produced two therapeutically distinct drugs from different parent peptides:

Complementary Therapeutic Profiles#

Semax and Selank address different aspects of CNS function and are sometimes described as complementary rather than competing agents:

• Semax targets the motivational, attentional, and neurotrophic axis: BDNF/NGF upregulation, dopamine potentiation, and neuroprotection in ischemic injury
• Selank targets the emotional, anxiolytic, and immunoregulatory axis: GABA receptor modulation, anxiety reduction, and immune system regulation

This functional complementarity has led to interest in combination use, though no controlled combination studies have been published.

Evidence Comparison#

Both peptides have similar evidence profiles: extensive Russian clinical use and preclinical studies in international journals, but no Western-standard Phase 3 trials. Semax has a somewhat larger body of mechanistic research published in English-language journals, particularly regarding BDNF/NGF upregulation and stroke neuroprotection.

Semax vs Cerebrolysin#

Cerebrolysin is the most broadly used neuroprotective peptide product and provides an important comparison point for Semax.

Fundamental Differences#

Mechanistic Comparison#

Both Semax and Cerebrolysin promote neurotrophic factor activity, but through different mechanisms:

• Semax upregulates endogenous BDNF and NGF expression through specific receptor binding (KD 2.4 nM) and transcriptional activation
• Cerebrolysin contains BDNF-like and NGF-like peptide fragments that directly activate neurotrophic signaling, plus it may stimulate endogenous neurotrophin production

The key practical advantage of Semax is its intranasal administration, which is non-invasive and allows self-administration. Cerebrolysin requires medical personnel for IV/IM injection and is typically administered in clinical settings.

Clinical Data Comparison#

Cerebrolysin has a substantially larger clinical evidence base, including international randomized controlled trials in stroke, Alzheimer's disease, and traumatic brain injury. However, results have been mixed, and Cerebrolysin has not received FDA approval despite multiple review attempts. Semax's clinical data is more limited in scope but is supported by regulatory approval in Russia and decades of post-marketing experience.

Semax vs Pinealon#

Pinealon (Glu-Asp-Arg) is a tripeptide from the Khavinson peptide bioregulator school of Russian peptide pharmacology, which represents a fundamentally different approach to neuropeptide therapeutics.

Design Philosophy Differences#

Pinealon's advantage lies in its simplicity and oral bioavailability, which is unusual for peptides. However, its evidence base is substantially smaller than Semax's, and it has not achieved regulatory approval in any jurisdiction.

Semax vs Dihexa#

Dihexa represents a newer generation of cognitive peptides with a different mechanistic basis.

Mechanistic Contrast#

Dihexa has attracted attention for its extraordinary potency in preclinical models, with cognitive effects at picomolar concentrations. However, it remains in very early development with no human safety or efficacy data. Semax's advantage is its established clinical safety profile and decades of human use, even though this experience is primarily from Russian medical practice.

Comparison Summary Table#

Evidence Gaps#

• No head-to-head comparison trials between Semax and any of these peptides
• Combination therapy data (particularly Semax + Selank) not available from controlled studies
• Comparative pharmacokinetic profiles in humans not established
• Relative efficacy for specific cognitive domains (attention, memory, executive function) not compared
• Long-term comparative safety data absent

Related Reading#

• Semax overview and research guide
• Semax research evidence
• Semax dosing protocols